Adma Biologics Incの収入

Adma Biologics Incの収入 は何ですか。

Adma Biologics Incの収入 は34.789M$です。

収入 の定義は何ですか。

普通株主に帰属する当期純利益は、純利益から優先配当金を差し引いた金額です。優先配当

Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.

NASDAQのセクタHealth Careにおける収入 の企業と比べるAdma Biologics Inc

Adma Biologics Incは何をしますか。

adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.

Adma Biologics Incと類似の収入